On Tuesday, Aquestive Therapeutics Inc (NASDAQ:AQST) released topline pharmacokinetic (PK) data from the temperature / pH study of its product candidate Anaphylm (epinephrine) Sublingual Film. Anaphylm is the company’s first and only orally administered epinephrine prodrug product candidate under development for severe life-threatening allergic reactions, including anaphylaxis. In March, Aquestive Therapeutics released topline clinical data from its Phase 3 PK study of Anaphylm, meeting all prim
Anaphylm pharmacokinetic results unaffected by oral cavity exposure to liquids of different temperatures and pHRemains on track to complete Anaphylm supportive clinical studies and expects to request pre-NDA meeting with FDA in the third quarter 2024Continues to anticipate filing a New Drug Application (NDA) shortly after completion of its pediatric study of Anaphylm WARREN, N.J., June 25, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a phar
Ideally, your overall portfolio should beat the market average. But the main game is to find enough winners to more...